PTO/SB/08a (08-03)
Approved for use through 97/31/2006, ONB 0651-0201
U.S. Patient and Trademark Office, U.S. DEPARTMENT OF COMMERCE to a collection of information unfers it contains a valid OMS control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)
, and the second

Application Number		10790723
Filing Date		2004-03-03
First Named Inventor Joo F		Ho LEE
Art Unit		2826
Examiner Name	Fetsum, Abraham	
Attorney Docket Numb	er	2336-247

				U.S.	PATENTS			Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant R		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1	6228675	B1	2001-05-08	Agilent Techn	nologies, Inc.				
	2	6492194	B1	2002-12-10	Thomson-CS	SF.				
If you wish	to ac	dd additional U.S. Pate	nt citatio	n information pl	lease click the	Add button.		Add		_
			U.S.P	ATENT APPLI	CATION PUB	LICATIONS		Remove		_
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Name of Patentee or Appli of cited Document			Releva	Columns,Line nt Passages o Appear		
	1	20020185712	A1	2002-12-12						
If you wish	to ac	dd additional U.S. Publ	ished Ar	olication citation	n information	nlease click the Ad	d button	Add		
.,				FOREIGN PAT				Remove		_
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²			Name of Patente Applicant of cited Document	e or	Pages,Column where Relevan Passages or Re igures Appea	t elevant	т.
	1	19800574	DE		1999-07-15					
	2	19700734	DE		1998-07-16					

,		d additional Foreign Patent Document citation information please click the Add b NON-PATENT LITERATURE DOCUMENTS	Remove	_			
Examiner Initials*	Cite No	nclude name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), ubblisher, citly and/or country where published.					
	1	German Patent Office, Office Action mailed June 1, 2006 and English translation thereo	f				
If you wis	n to a	d additional non-patent literature document citation information please click the	Add button Add	_			
		EXAMINER SIGNATURE					
Examiner	Signa	ure Date Consider	ed				

1 See Kind Codes of USPTO Patent Documents at year, USPTO_GOV or MPEP 901.6.2 Extens office that issued the document, by the ho-other code (WIPO Standard ST.3.) 27% plaquese petited colouresh, by mandation of the year of the Preprior count presence the serial number of the Patent document.

1 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 9 Applicant is to place a check mark here if English language transition in attached.

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number Filing Date			10790723
			2004-03-03
	First Named Inventor	Joo H	lo LEE
Art Unit			2826
	Examiner Name	Fetsu	ım, Abraham
Attorney Docket Number		er	2336-247

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication of from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information sideosure statement. See 37 CFR 197(a)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/BENJAMIN J. HAUPTMAN/	Date (YYYY-MM-DD)	2006-08-31
Name/Print	Benjamin J. Hauptman	Registration Number	29310

This collection of information is required by 3 T CPR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C. 12 G. and 3 T CPR.

1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. There will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Trademark Office, U.S. Operatment of Comments. P. D. 68. 1436, Alexandria, V.S. 2311.1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.A. 2311.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is \$3 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2504 and 2506. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the state of the s
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.